The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review ; day:9 ; month:1 ; year:2018 ; pages:1-16
Drug safety ; (9.1.2018), 1-16
- Keyword
-
Kardiovaskuläre Krankheit
- Creator
-
Nurmohamed, Michael
- Contributor
-
Choy, Ernest
Lula, Sadiq
Kola, Blerina
DeMasi, Ryan
Accossato, Paola
SpringerLink (Online service)
- DOI
-
10.1007/s40264-017-0628-9
- URN
-
urn:nbn:de:1111-201803013902
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nurmohamed, Michael
- Choy, Ernest
- Lula, Sadiq
- Kola, Blerina
- DeMasi, Ryan
- Accossato, Paola
- SpringerLink (Online service)
Other Objects (12)
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review
Biologics in therapy
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review
Biologics in therapy
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study
Biologics, cardiovascular effects and cancer
Editorial: Methods in cardiovascular biologics and regenerative medicine
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases
Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis
Rheumatic diseases and obesity: adipocytokines as potential comorbidity biomarkers for cardiovascular diseases
Rheumatic diseases and sport
Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review